Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah, kind of pisses me off that the company can come up with a bunch of great PR's prior to doing their offering deal but when everyone is drowning can't think of a single thing positive to let shareholders know about in the companies future... So for over a year they were working on a covid drug and not even a peep... people only found out Tuesday because ClinicalTrials.gov posted it up on their government site.
No telling if a PR will be out before the next quarter, which should be due in the next couple weeks. The quarterly could very well update where thing stand, and what the company is planning in the foreseeable future.
Gary
Be nice to see some PR come out soon and say all convertibles paid off.. hell enough shares have been issued since early this year.
Do you have some inside info on this it sure seems like someone has shared it with every hedge fund that shorts stocks?... I am not sure if this management is really trust worthy with company secrets as it seems like the shorts always seem to be able to anticipate every move here.
Do you have some inside info on this it sure seems like someone has shared it with every hedge fund that shorts stocks?... I am not sure if this management is really trust worthy with company secrets as it seems like the shorts always seem to be able to anticipate every move here.
Explain the catalyst your banking on.. the CEO getting caught raping another employee? Every person that took part in the trials last year dropping dead tomorrow? Not sure how your coming up with a below Market Cap PPS there. Also, Sec going after trading groups right now... I love working independently don't have to worry about getting caught up in anything like that.
This guy was a front loader... BUSTED big time.
https://www.justice.gov/usao-sdny/press-release/file/1444651/download
LOL. OK. I hope I can catch it when I buy it for $0.37-42 in December
YummmE. Love when a Post ages sooooooo very well. ;)
Didn't get pumped... there was a discovery yesterday company working on Covid drug... not any rumor or made up story was a posting of a new trial on the FDA Clinical Trials.gov site. What I witnessed in the opening today was Barcoding algo that wouldn't let anything touch the ask while bid whacking... A program run like that is about as illegal as they come... There was a huge amount of volume that hit and... there is someone involved with manipulating this ticker in a massive way. I hope the FEDS lock their ass up...
Looks like you got pumped and dumped on.
See you over a buck today!!!!
I like that a lot that this post bothered you sooooooo much you archived it. I literally controlled yoor brain for months. LOL
Okay, our CMO chief medical officer... Is a big whig with the Melinda Gates Research Foundation over by Pifzer officer.... this guy Michael Dunne was the old vice president of Pifzer... now we have shifted some gears early last year working on a Covid drug the one our past president suggested... could be onto something big here... even though this discovered trial today was withdrawn we need to know what is going on did they have a breakthrough drug they created...
https://clinicaltrials.gov/ct2/show/record/NCT05026801?
term=iterum&draw=2&rank=1
Hopefully news in the morning.
Today the VOLUME kicked up nearly a million shares at 1:30 PM. VOLUME kept strong until 3 PM and then dwindled smaller, BUT THEN really big Volume afterhours.
Between 4:30 PM and 7:30 PM over 2 million shares traded.
They could have withdrawn to just to focus on their other drug first then go back at it big here..... We don't know till Corey Fishman tells us what's going on but they are obviously working on things.
Does not mean they could make changes to it... the important thing is they have something else in the pipeline they are working on... could be a lot more not disclosed...
Thanks for the response, but --- look closely at that link - it clearly states that the recruitment status is WITHDRAWN (due to inadequate support to carry out study).
If that is the reason for the jump today people are delusional.
Enjoy the Chase.....
People found out Iterum has secretly been working on a COVID DRUG with Michael DUNNE.... getting ready to try to start some kind of trials with it ... Azithromycin Plus Hydroxychloroquine for COVID-19 Infection
https://clinicaltrials.gov/ct2/show/record/NCT05026801?term=iterum&draw=2&rank=1
Tom 8am News IMO
All of that is true, but it does not explain why we saw the big volume and price spike in ITRM today.
I would think that ITRM will be providing 3rd quarter results in the near future. With those results I would think that they'd provide further guidance on what's being planned to work toward FDA approval. Perhaps something else is coming as well, but I suspect guidance will come in the quarterly.
Gary
Extremely large Volume for the day. Some imminent news?
what's up with all these form T trades after hours?
Doesn't mean they couldn't be reworking it ... they may have put together something they are going to go after.. I bet there is more going on just not disclosed because of the privacy rules.
Hi that study was withdrawn
Itrm working on drug Azithromycin Plus Hydroxychloroquine for COVID-19 Infection
https://clinicaltrials.gov/ct2/show/record/NCT05026801?term=iterum&draw=2&rank=1
Itrm was going after a covid drug too look...
https://clinicaltrials.gov/ct2/show/NCT05026801?term=iterum&draw=2&rank=1
Yes, Thanks Jack for posting... nice when people decide to contribute to the stock we hold.
Nice read on ITRM Jack,Thanks for posting
I have avg down myself GLTA
You would think there would be something to update shareholders on now for plans going forward...
Not letting Manipulators sway me from here.
https://www.griproom.com/fun/10-signs-your-stock-is-being-manipulated
$ITRM definitely getting some pump now person on Twitter with 58.6K followers tweeting this in last hour...
$WISH turned into a $9,905 score today always on the action and have alerts 🚨 set on all my @MrZackMorris picks $CEI $FUBO $ITRM $BBIG $AHT and a few others along the ride pic.twitter.com/cocGBfnLQc
— ProTrader_Mike (@ProTrader_Mike) October 20, 2021
Great read on $ITRM https://pennystocks.today/itrm-stock-pharmaceutical-dud-or-run-up/
Look at Highlighted area discussed various potential paths forward... well it appears one thing they did do was open one of the studies back up with expanded access... I don't know company saying zero to shareholders... crappy but could be one of these paths forward... other part of trial creation would have thought figured something out by now.. but nothing changed except that completed study now open on FDA gov site.
Look at third footnote.... they have opened a existing trial back up for expanded access it's available and has been for a little while.. I think this is the route company going after FDA approval. Instead of starting new trial... otherwise why would they have not created one by now?
https://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-applications-clinical-treatment-expanded-access-overview
Bill Clinton is out of hospital from his yeast infection I mean UTI.....
Well sure hope this brings some Volume here..
Must further stay in hospital so can receive IV treatment... if only FDA approved ours he could be given pills and sent home.... lol
https://www.msn.com/en-us/health/medical/bill-clinton-reportedly-to-be-released-soon-from-uci-medical-center/ar-AAPBXWr?ocid=msedgntp
Well, if Bill Clinton could have been just given a pill to take twice a day and not have to remain in hospital with IV care I bet he would have enjoyed a lot more privacy of his medical problem... Probably, sitting to long through some boring ceremony they always have to do while trying to not hold it or he is back at it with Monica. Lol
With Bill Clinton's track record the urinary tract infection could be sexually transmitted.
Good luck. Let the board know what you find out or even if no one will receive your call. Thanks
They have to be careful they about dispensing non-public information. There are disclosure rules and processes that must be followed by management.
Bill Clinton Hospitalized in ICU with Urinary Tract Infection.
Wonder if he will be part of our study right now.....
If only the FDA provided another option for like Itrm too.... lol
https://www.msn.com/en-us/health/medical/former-president-bill-clinton-hospitalized-at-uci-medical-center-in-orange-he-is-on-the-mend/ar-AAPxsny?ocid=msedgntp
I am going to be on the phone Monday.. too I have a large position here and want to know why I can't get a return email.
I watch the tape all day long and when it starts to get some buying... low and behold the five digit to the right of decimal trades immediately take over and don't stop till it drops along with bid whack trades... Nothing is organic here... MM's are absolutely manipulating this.... in a big way. when they start running trades that don't touch the Ask or the Bid leaving it unchanged is the perfect for these companies to naked short with algo's I believe... people always say prove it... not like anyone will let you access their programs etc.. If the SEC can't enforce it should be someone that can because right now... I feel like this could have move many times from retail and would have but always gets bid whacked then manipulated all dam day long on the trades... Those institution volumes don't even make a dent in this... also the SEC rules force position holders to disclose what they are holding but nothing gets disclosed on large short positions small oversight.
This will give you an idea of institutional rotation as of 6/302021 by Nasdaq.com
This is normal rotation. Not everything is manipulation.
It is also not out of the norm for these early stage bios to go through cycles like this.
Disclaimer: I am not a stockholder at present, but watching, doing dd and evaluating. Any entry will be TA based.
Here is a daily look.
Stock Market hitting all time Highs but this COMPLETELY MANIPULATED UNDERVALUED STOCK CAN'T GO UP A TICK... Company and Hedge Connections at this point should be investigated ... Odd company just does not want to work harder to update a real update for it's share holders.
Itrm MM's sure looks like trying to keep flippers out while big accumulation is occurring super cheap here.
Followers
|
84
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2198
|
Created
|
10/23/19
|
Type
|
Free
|
Moderators |
Fellow penny flippers, a week or 2 ago, someone posted about ITRM and it grabbed my attention immediately. Partially because its a Bio stock and another reason is the technical setup/gaps looked promising. I have dived into the company further and posting my DD:
Provide DD for bullish sentiment
Iterrum Therapeutics is a Biotech company backed by some very well known prominent industry veterns / team. There primary product is Sulopenum which is developed by Pfizer in the 1980s, shelved due to Pfizers other product focus. ITRM's staff is compromised of the well known bio legend - Alex Denner who owns Sarissa Capital. Alex Denner is more prominently known as the head of Carl Ichans bio division who spearheaded his portfolio and knows the Bio industry inside/out. Denner left Ichan's bio portfolio to spinoff Sarissa Capital and leverage his decades of knowledge. Sarissa Capitals' main focus in investing in bio stocks with the intention of buyouts (Denner & MDCO --- Medicines company buyout $9.7 billion.
A large majority of ITRM staff and board are from a very well known company back in 2005 Duratta / Vicuron boards. Back in 2005, Vicuron was developing a drug that passed the NDA for andidulafungin for fungal infections. Pfizer jumped in after NDA approval and bought Vicuron out for $1.8 billion as it was a revolutionary drug.
source: Pfizer buy out Vicuron $1.9 billion merger
What ended up happening at Pfizer was Vicuron had to now go through FDA approvals. From the little research available back then, it appears Vicuron ended up getting shelved as there was a lot of R&D involved and too expensive to push forward (Dunne link below shows Pfizer splitting off from R&D, trial, FDA approval costs). Vicuron ended up being bought by Durata (source: https://www.pharmaceutical-business-review.com/news/durata_acquires_vicuron_from_pfizer_091221-2/. Duratta picks up where Pfizer left off, conducted the studies, R&D, and NDA/FDA process. When Vicuron's drug become close, Duratta reached back out to Pfizer to continue the trial study to keep moving forward. Pfizer had to fork up another $6million apart of their licensing deal
(source: Faded star at Pfizer leads to discounted $68M IPO for Durata
What ended up happening 2 years later in 2014? Actavis buys out Durata for $675 million @ $23 a share, prior to buyout, stock was trading at $11. (source: Durata stock graph.
source: Actavis snaps up Durata, newly approved antibiotic in $675M buyout
After this buyout in 2014, ITRM was formed. A large amount of the Board of Directors, Senior Management are from the previous buyout. There prior Durata employees and now focusing their efforts on ITRM.
source: ITRM Board of Directors & Senior Mgmt
Sulopenum
Pzier chief scientist Michael Dunne left Pfizer to work at ITRM. He was the scientist behind a lot of Pfizer's major drugs. He currently resigned from ITRM for a new opportunity -- working as Chief Scientist at the Bill & Melinda Gates Foundation. Back in 2017 as he was speaking on behalf of ITRM / Sulopenum, he had a very strong positive sentiment to the drug when it gets the NDA / FDA passed:
While this is an old compound, sulopenem has good patent protection. The IV product should garner ten years of regulatory exclusivity in the U.S. due to its status as a “Qualified Infectious Disease Product”. Given that the oral form of sulopenem is an NCE, patent protection for this version exists through 2028 with the possibility of Hatch-Waxman as well as pediatric use extensions.
Source: Former Pfizer Scientist Is Resurrecting Projects To Solve The Multidrug Resistant Bacteria Problem
NDA Approval
NDA approval is set for end of January or potentially first week of February. They had a preliminary meeting back in Sept 2020.
Positive Pre-NDA Meeting with FDA for Sulopenem - 95% approval from ITRM Board
The same board members, staff, and ties on the Duratta deal are now working at ITRM. Almost all of ITRM employees are from Durrata. During the NDA filing review, Pfizer had some senior members during the NDA review with FDA (pre filing). Some names -- Treacy Vargas (worked at Pfizer for 17yrs, retired, and ITRM brought her out of retirement to be head of their submission applications). They brought her in on contract, then after they submitted the NDA in October, she left.
Sarissa Capital & Alex Denner
Alex & Sarissa are known from above link and many others of turning Bio companies in to large profitable buyouts. Sarissa currently owns 33% of ITRM with a special clause for obtaining 60% total ownership of the outstanding shares.
Sarissa discloses 33% ownership of ITRM
Alex& Sarissa have a clause where after Jan 21, they can invoke the exchange of exchangeable notes to take FULL ownership of ITRM after NDA approval. Sarissa AGM meeting for exchangeable notes. So they have a additional 27% ish to exchange if they want. Starting of the ability to exercise I think is Jan 21 from the filing: ITRM AGM Meeting & Sarissa Ownership clause vote
Current outstanding shares is roughly 70-85% are owned by Sarissa, RA Capital, and other institutions / insiders.
source:ITRM Share distribution / ownership
SO WHAT?
If you haven't read between the lines this far and clued the pieces together, this may be a potential buyout under the covers. Past Durata employees are familiar with what it takes to pass NDA / FDA approvals. Chief Scientist Michael Dunne has been developing this drug and trials since 2015, he also advocates that a NDA approval and distribution would cause this drug to have a EconomicMoat (Warren Buffet talks a lot about Economic Moat companies).
The potential here is after NDA and possibly prior to the FDA or PDUFA approval in Mar/Apr, this could have Pfizers eye along with a few large pharma companies. The current market cap of ITRM is around $100 million which is absolutely peanuts when compared to a blockbuster drug (500-1billion market cap). This could potentially mean a large buyout anywhere from $10-20 / share. However a fair warning, this is very speculative play but given the consensus of Durata previous staff now at ITRM, Pfizer drug that is in a market sector that has no new competitor in 20years, and Sarisa / Alex Denner eyeing for a ownership stake of ITRM, the sentiments are pointing to a positive influx of catalysts over the coming months.
This is a 1st mover advantage in a market that has traditionally been stagnant. My wife works in the medical field and a lot of the verbage is confusing, so I had her review Supolenum. Her findings were this is a fairly well received new drug and something that is much needed in the space. General UTI drugs have terrible side effects and cause intestine and gut bacteria which results in additional anti-biotics. Selopenum has similar side effects, however, much lower then the older products on the market.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |